ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

ADMA Biologics achieves first-time profitability, anticipates substantial revenue growth

ADMA Biologics reported strong Q1 2023 earnings, achieving first-time adjusted EBITDA profitability and a significant year-over-year increase in total revenues. The company is well-positioned in the biopharma market, with a focus on rapid transformation, increased sales, and cost efficiencies. While navigating strategic alternatives and pursuing new growth opportunities, ADMA remains conservative in its guidance, emphasizing long-term growth and potential revenue targets.

ADMA Biologics reports robust Q2 earnings, raises revenue guidance

ADMA Biologics reported strong financial performance, with significant revenue growth and raised revenue guidance. The company's focus on serving immune deficient underserved patients and commitment to enhancing profitability through various initiatives bode well for its future.

ADMA Biologics reports robust Q3 earnings, focuses on ASCENIV growth

ADMA Biologics delivered strong financial results, revised revenue guidance higher for the coming years, and demonstrated a strategic focus on product development and market expansion. While facing potential financial constraints and product mix challenges, the company has opportunities to drive growth through patient advocacy and supply chain enhancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

For a company that just racked up two significant regulatory wins, ADMA Biologics Inc.

ADMA Biologics: Selloff Creates Buying Opportunity

Aurora Cannabis

Cleveland-Cliffs

Evofem Biosciences Inc

Inseego

OrganiGram Holdings Inc.

Zynga

These seven cheap stocks under $10 all have massive upside potential according to Wall Street's top analysts.
The post 7 High-Quality Cheap Stocks to Buy With $10 appeared first on InvestorPlace.

7 High-Quality Cheap Stocks to Buy With $10

After years of struggle, ADMA Biologics appears at last to be poised for bigger things.

ADMA Biologics Is De-Risked and Ready to Rise

Shares have lost over a third of their value during the past three years.

ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The Year

Since April, ADMA has won approval for two IVIG products, Asceniv and Bivigam, as well as approval to manufacture them in its vertically integrated facility.

ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside

Advaxis

Novartis

Roche Holding AG

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Microcap specialty pharma company ADMA Biologics Inc. advanced in the last two trading days in anticipation of a binary event, and with the event materializing in favor of the company, the stock has taken another leg up.

ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday.

ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

Back on December 19th, ADMA Biologics (ADMA) received a complete response letter "CRL" from the FDA concerning their PAS for BIVIGAM.

ADMA Biologics Investors Prepare For RI-002 PDUFA

News for ADMA Biologics Stock (ADMA)